Halia Therapeuticsincis A Clinical Stage Biopharmaceutical Company Located In Lehiutahthe Company Is Focused On Developing Innovative Treatments For Chronic Inflammatory Disorders And Neurodegenerative Diseaseshalia Therapeutics Aims To Improve Patient Quality Of Life By Creating Novel Therapeutics That Address The Root Causes Of Inflammation Driven Diseases The Company Is Advancing A Pipeline Of Differentiated Small Moleculesincluding Its Lead Candidate Ht 6184A First In Class Nek7 Nlrp3 Inflammasome Inhibitorthis Compound Is Designed To Target Metaflammation Related To Obesity And Metabolic Dysfunction And Is Also Being Explored For Lower Risk Myelodysplastic Syndromesother Candidates In Development Include Ht 4253A Lrrk2 Inhibitoralong With Several Additional Compounds Targeting Various Inflammatory And Neurodegenerative Conditions Halia Therapeutics Has Received The Novo Nordisk Golden Ticketwhich Supports Its Research Efforts And Enhances Its Position In The Biotech Ecosystemthe Company Is Committed To Delivering Impactful Solutions For Patients Worldwide
